US 11,980,659 B2
Consensus prostate antigens, nucleic acid molecule encoding the same and vaccine and uses comprising the same
David Weiner, Merion, PA (US); Jian Yan, Wallingford, PA (US); Bernadette Ferraro, La Jolla, CA (US); Niranjan Y. Sardesai, Blue Bell, PA (US); and Mathura P. Ramanathan, Ardmore, PA (US)
Assigned to The Trustees of the University of Pennsylvania, Philadelphia, PA (US); and Inovio Pharmaceuticals, Inc., Plymouth Meeting, PA (US)
Filed by The Trustees of the University of Pennsylvania, Philadelphia, PA (US); and Inovio Pharmaceuticals, Inc., Plymouth Meeting, PA (US)
Filed on Jun. 28, 2021, as Appl. No. 17/360,342.
Application 17/360,342 is a division of application No. 15/884,594, filed on Jan. 31, 2018, granted, now 11,045,535.
Application 15/884,594 is a continuation of application No. 15/207,271, filed on Jul. 11, 2016, granted, now 9,913,885.
Application 15/207,271 is a continuation of application No. 14/552,030, filed on Nov. 24, 2014, granted, now 9,399,056.
Application 14/552,030 is a continuation of application No. 13/883,978, granted, now 8,927,692, previously published as PCT/US2011/060592, filed on Nov. 14, 2011.
Claims priority of provisional application 61/417,817, filed on Nov. 29, 2010.
Claims priority of provisional application 61/413,176, filed on Nov. 12, 2010.
Prior Publication US 2022/0016228 A1, Jan. 20, 2022
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 38/00 (2006.01); A61K 39/00 (2006.01); C07K 14/47 (2006.01); C12N 9/48 (2006.01); C12N 9/64 (2006.01)
CPC A61K 39/001193 (2018.08) [A61K 39/0011 (2013.01); A61K 39/001194 (2018.08); A61K 39/001195 (2018.08); C07K 14/4748 (2013.01); C12N 9/485 (2013.01); C12N 9/6424 (2013.01); C12Y 116/01 (2013.01); C12Y 304/17021 (2013.01); C12Y 304/21077 (2013.01); A61K 39/00 (2013.01); A61K 2039/53 (2013.01); A61K 2039/884 (2018.08)] 19 Claims
 
1. A nucleic acid molecule comprising a coding sequence encoding one or more proteins selected from the group comprising:
a) SEQ ID NO:2, a protein that is at least 95% identical to SEQ ID NO:2, provided amino acids 69, 78, 80, 82, 102, 110, 137, 139, 165, 189, 203, 220, 232 and 248 of SEQ ID NO:2 are conserved, or an immunogenic fragment of SEQ ID NO:2 comprising amino acids corresponding to at least 256 amino acid residues of SEQ ID NO:2 provided amino acids 69, 78, 80, 82, 102, 110, 137, 139, 165, 189, 203, 220, 232 and 248 of SEQ ID NO:2 are conserved;
b) SEQ ID NO:4, a protein that is at least 95% identical to SEQ ID NO:4, provided amino acids 21, 86, 127, 129, 154, 156, 182, 195, 206, 218, 220, 237, 249, 255, 265, 271 or 275 of SEQ ID NO:4 are conserved, or an immunogenic fragment of SEQ ID NO:4 comprising amino acids corresponding to at least 274 amino acid residues of SEQ ID NO:4, provided amino acids 21, 86, 127, 129, 154, 156, 182, 195, 206, 218, 220, 237, 249, 255, 265, 271 or 275 of SEQ ID NO:4 are conserved;
c) SEQ ID NO:6, a protein that is at least 95% identical to SEQ ID NO:6, provided amino acids 14, 15, 32, 47, 58, 79, 111, 157, 223, 320, 350, 475, 499, 569, 613, 624, 653, 660, 663, 733 and 734 of SEQ ID NO:6 are conserved, or an immunogenic fragment of SEQ ID NO:6 comprising amino acids corresponding to at least 735 amino acid residues of SEQ ID NO:6, provided amino acids 14, 15, 32, 47, 58, 79, 111, 157, 223, 320, 350, 475, 499, 569, 613, 624, 653, 660, 663, 733 and 734 of SEQ ID NO:6 are conserved;
d) SEQ ID NO:8, a protein that is at least 95% identical to SEQ ID NO:8, provided amino acids 21, 31, 32, 49, 64, 75, 96, 128, 174, 240, 337, 367, 492, 516, 565, 586, 630, 641, 670, 677, 680, 750, and 751 of SEQ ID NO:8 are conserved, or an immunogenic fragment of SEQ ID NO:8 comprising amino acids corresponding to at least 752 amino acid residues of SEQ ID NO:8, provided amino acids 21, 31, 32, 49, 64, 75, 96, 128, 174, 240, 337, 367, 492, 516, 565, 586, 630, 641, 670, 677, 680, 750, and 751 of SEQ ID NO:8 are conserved;
e) SEQ ID NO:10;
f) SEQ ID NO:12, a protein that is at least 95% identical to SEQ ID NO:12, or an immunogenic fragment of SEQ ID NO: 12 comprising amino acids corresponding to at least 349 amino acid residues of SEQ ID NO: 12; or
g) SEQ ID NO:14, a protein that is at least 95% identical to SEQ ID NO:14, or an immunogenic fragment of SEQ ID NO: 14 comprising amino acids corresponding to at least 129 amino acid residues of SEQ ID NO:14.